• Lunai Bioworks’ Nasdaq-listed common stock is expected to be suspended from trading at the opening of business on October 30, 2026.
• Nasdaq’s October 21, 2026, delisting determination cited noncompliance with its $2.5 million minimum stockholders’ equity requirement.
• The company reported a $9.02 million stockholders’ deficit for the fiscal year ended June 30, 2026.
• It will not seek a hearing; voluntary delisting is expected to take effect on or about November 12, 2026.
• No over-the-counter quotation is planned, leaving the common stock without an assured trading market following the suspension.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610221900PR_NEWS_USPR_____LA79456) on October 22, 2026, and is solely responsible for the information contained therein.